TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Diabetes Efforts Across Language and Literacy (IDEALL)
Brief Summary: The IDEALL Project (Improving Diabetes Efforts Across Language and Literacy) is a 3-arm randomized controlled trial to explore contextual factors at the patient, clinician, and organizational level of two patient self-management support strategies. A communication technology-based intervention (automated telephone diabetes management) and an interpersonally-oriented intervention (group medical visits)will be compared to usual care for their ability to improve diabetes outcomes among vulnerable populations in 4 safety-net health centers in the University of California, San Francisco (UCSF) Collaborative Research Network.


Options:
A: Arm Label: TLC-CPAP; Type: EXPERIMENTAL; Interventions: Device: Telecommunications system | Arm Label: TLC-Control; Type: PLACEBO_COMPARATOR; Interventions: Other: TLC-Control | Intervention Type: DEVICE; Name: Telecommunications system; Assigned to Arm(s): TLC-CPAP | Intervention Type: OTHER; Name: TLC-Control; Assigned to Arm(s): TLC-Control
B: Arm Label: Safety Training; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Safety Training | Arm Label: Personal Health Partner and Counseling (PHP+C); Type: EXPERIMENTAL; Interventions: Behavioral: Personal Health Partner and Counseling (PHP+C) | Intervention Type: BEHAVIORAL; Name: Safety Training; Assigned to Arm(s): Safety Training | Intervention Type: BEHAVIORAL; Name: Personal Health Partner and Counseling (PHP+C); Assigned to Arm(s): Personal Health Partner and Counseling (PHP+C)
C: Arm Label: ATSM Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ATSM Intervention | Arm Label: WAIT LIST Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ATSM Intervention; Assigned to Arm(s): ATSM Intervention
D: Arm Label: ATSM Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ATSM Intervention | Arm Label: GMV Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: GMV Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ATSM Intervention; Assigned to Arm(s): ATSM Intervention | Intervention Type: BEHAVIORAL; Name: GMV Intervention; Assigned to Arm(s): GMV Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Diabetes Efforts Across Language and Literacy (IDEALL)
Brief Summary: The IDEALL Project (Improving Diabetes Efforts Across Language and Literacy) is a 3-arm randomized controlled trial to explore contextual factors at the patient, clinician, and organizational level of two patient self-management support strategies. A communication technology-based intervention (automated telephone diabetes management) and an interpersonally-oriented intervention (group medical visits)will be compared to usual care for their ability to improve diabetes outcomes among vulnerable populations in 4 safety-net health centers in the University of California, San Francisco (UCSF) Collaborative Research Network.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Patient video decision aid & telephone coaching | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Printed educational brochure | Intervention Type: BEHAVIORAL; Name: Patient video decision aid & telephone coaching; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Printed educational brochure; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: UNITED Planned Care; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Voice Response System | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-Led Group Clinic Visits | Intervention Type: BEHAVIORAL; Name: Interactive Voice Response System; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Nurse-Led Group Clinic Visits; Assigned to Arm(s): 2
D: Arm Label: ATSM Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ATSM Intervention | Arm Label: GMV Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: GMV Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ATSM Intervention; Assigned to Arm(s): ATSM Intervention | Intervention Type: BEHAVIORAL; Name: GMV Intervention; Assigned to Arm(s): GMV Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bifocal Soft Contact Lenses - Do They Slow Progression of Myopia Relative to Single Vision Soft Contact Lenses in Children and Adolescents?
Brief Summary: The purpose of this study is to determine whether bifocal soft contact lenses are effective in controlling the progression of myopia in children and adolescents that exhibit a tendency to excessively cross their eyes while reading (esophoria or eso fixation disparity). Several studies have demonstrated that bifocal or progressive multifocal spectacles are effective in slowing the progression of myopia in children either with near point esophoria and/or with inadequate focusing at near. A prominent theory for one cause of myopia progression is that poorly focused images on the back of the eye (retina) cause the eye to lengthen, causing an increase in myopia. Bifocal contact lenses may reduce this retinal defocus, reducing the stimulus to eye elongation, and thus may reduce myopia progression.


Options:
A: Arm Label: Bifocal spectacles; Type: ACTIVE_COMPARATOR; Interventions: Device: Bifocal spectacles | Arm Label: Prismatic bifocals; Type: ACTIVE_COMPARATOR; Interventions: Device: Prismatic bifocal spectacles | Arm Label: Single vision spectacles; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bifocal spectacles; Assigned to Arm(s): Bifocal spectacles | Intervention Type: DEVICE; Name: Prismatic bifocal spectacles; Assigned to Arm(s): Prismatic bifocals
B: Arm Label: Test lens C; Type: EXPERIMENTAL; Interventions: Device: 1 Day Acuvue Moist | Arm Label: Test lens A; Type: ACTIVE_COMPARATOR; Interventions: Device: 1 Day Acuvue Moist | Intervention Type: DEVICE; Name: 1 Day Acuvue Moist; Assigned to Arm(s): Test lens A, Test lens C
C: Intervention Type: DRUG; Name: Atropine Eye drops; Assigned to Arm(s): N/A
D: Arm Label: Bifocal Contact Lenses; Type: EXPERIMENTAL; Interventions: Device: Bifocal Contact Lenses | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo Control | Intervention Type: DEVICE; Name: Bifocal Contact Lenses; Assigned to Arm(s): Bifocal Contact Lenses | Intervention Type: DEVICE; Name: Placebo Control; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Randomized Clinical Trial of the Alair System for the Bronchial Thermoplasty Treatment of Asthma
Brief Summary: The purpose of this study is to demonstrate the effectiveness and safety of the Alair System for the treatment of asthma.

This will be a multicenter, randomized controlled study comparing the effects of treatment with the Alair System to standard drug therapy. One-hundred and ten subjects will be randomized 1:1 to either the Alair Group (Medical management + Alair treatment),or Control Group (Medical management only).


Options:
A: Arm Label: Alair Group; Type: N/A; Interventions: Device: Bronchial Thermoplasty with the Alair System | Intervention Type: DEVICE; Name: Bronchial Thermoplasty with the Alair System; Assigned to Arm(s): Alair Group
B: Arm Label: Alair; Type: EXPERIMENTAL; Interventions: Device: Alair System | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Alair System | Intervention Type: DEVICE; Name: Alair System; Assigned to Arm(s): Alair | Intervention Type: DEVICE; Name: Alair System; Assigned to Arm(s): Sham
C: Arm Label: Alair Group; Type: EXPERIMENTAL; Interventions: Procedure: Bronchial thermoplasty with the Alair System | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional therapy with ICS+LABA | Intervention Type: PROCEDURE; Name: Bronchial thermoplasty with the Alair System; Assigned to Arm(s): Alair Group | Intervention Type: DRUG; Name: Conventional therapy with ICS+LABA; Assigned to Arm(s): Control Group
D: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Procedure: Bronchial Thermoplasty with the Alair System | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Control | Intervention Type: PROCEDURE; Name: Bronchial Thermoplasty with the Alair System; Assigned to Arm(s): Treatment | Intervention Type: DRUG; Name: Control; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Randomized Clinical Trial of Bronchial Thermoplasty With the Alair System for the Treatment of Severe Asthma
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of the Alair System for the treatment of severe refractory asthma.

This will be a multicenter, randomized controlled study comparing the effects of treatment with the Alair System to standard drug therapy in patients with severe asthma refractory to standard medication therapy. A total of 30 subjects will be randomized 1:1 to the Alair Group (Medical management + Alair Treatment) OR the Control Group (Medical management only).


Options:
A: Arm Label: Alair; Type: EXPERIMENTAL; Interventions: Device: Alair System | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Alair System | Intervention Type: DEVICE; Name: Alair System; Assigned to Arm(s): Alair | Intervention Type: DEVICE; Name: Alair System; Assigned to Arm(s): Sham
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Procedure: Bronchial Thermoplasty with the Alair System | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Control | Intervention Type: PROCEDURE; Name: Bronchial Thermoplasty with the Alair System; Assigned to Arm(s): Treatment | Intervention Type: DRUG; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Alair Group; Type: EXPERIMENTAL; Interventions: Procedure: Bronchial thermoplasty with the Alair System | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional therapy with ICS+LABA | Intervention Type: PROCEDURE; Name: Bronchial thermoplasty with the Alair System; Assigned to Arm(s): Alair Group | Intervention Type: DRUG; Name: Conventional therapy with ICS+LABA; Assigned to Arm(s): Control Group
D: Arm Label: Alair Group; Type: N/A; Interventions: Device: Bronchial Thermoplasty with the Alair System | Intervention Type: DEVICE; Name: Bronchial Thermoplasty with the Alair System; Assigned to Arm(s): Alair Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Seroquel on Glucose Metabolism
Brief Summary: The purpose of this study is to determine whether six months treatment with the antipsychotic medicine Seroquel (quetiapine) may affect the schizophrenic patient's glucose metabolism


Options:
A: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Naltrexone 50mg; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Naltrexone 25mg; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone 25mg, Naltrexone 50mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: aripiprazole | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
D: Intervention Type: DRUG; Name: Seroquel (quetiapine); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Randomized, Open-label 3-arm, Parallel Group, Multicenter Phase IIIb Study Comparing Efficacy and Safety of Rosuvastatin 20mg and 40mg With That of Atorvastatin 80 mg in Subjects With Acute Coronary Syndromes
Brief Summary: Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes


Options:
A: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: rosuvastatin calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Randomized, Open-label 3-arm, Parallel Group, Multicenter Phase IIIb Study Comparing Efficacy and Safety of Rosuvastatin 20mg and 40mg With That of Atorvastatin 80 mg in Subjects With Acute Coronary Syndromes
Brief Summary: Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes


Options:
A: Intervention Type: DRUG; Name: MK0653A, ezetimibe (+) simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Rosuvastatin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: rosuvastatin calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
C: Arm Label: ABT-335 plus rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: ABT-335 plus rosuvastatin | Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: ABT-335 plus rosuvastatin; Assigned to Arm(s): ABT-335 plus rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Rosuvastatin Calcium | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Rosuvastatin Calcium | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: ABT-335, Drug: Placebo | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin Calcium, Drug: Placebo | Arm Label: E; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin Calcium, Drug: Placebo | Arm Label: F; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin Calcium, Drug: Placebo | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Rosuvastatin Calcium; Assigned to Arm(s): A, B, D, E, F | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): C, D, E, F

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis? A Cluster Randomised Controlled Trial in an East London Primary Care Trust
Brief Summary: This randomised controlled trial tests whether screening people registering with general practices cost-effectively increases the detection of tuberculosis. The study objectives are to:

1. recruit, and randomise with stratification, forty Hackney general practices to usual activity or screening for TB primarily during registration health checks (by practice nurses and GPs) and transfer-in visits for children (by health visitors)
2. implement a screening programme comprising education, resources and clinical support for intervention practices using proven behaviour change strategies
3. gather outcomes and costs
4. build research capacity within an ELENoR Primary Care Research Team and across a Primary Care Trust.

The primary outcome is the proportion of TB cases identified in primary care. The study is powered to detect a 20% increase (from 55% to 75%) in the detection of new cases of TB in primary care with 80% power at the 5% significance level. Secondary outcomes are rates of prophylaxis for latent TB infection (LTBI), BCG immunisation, smear negative (early) TB and costs. Analyses will be by intention to treat.


Options:
A: Intervention Type: BEHAVIORAL; Name: safety program; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: Screening for Tuberculosis; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Multi-Source Feedback: including self-assessment & coaching; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Opinion Leaders, Academic Detailing, Reminders, and Feedback; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis? A Cluster Randomised Controlled Trial in an East London Primary Care Trust
Brief Summary: This randomised controlled trial tests whether screening people registering with general practices cost-effectively increases the detection of tuberculosis. The study objectives are to:

1. recruit, and randomise with stratification, forty Hackney general practices to usual activity or screening for TB primarily during registration health checks (by practice nurses and GPs) and transfer-in visits for children (by health visitors)
2. implement a screening programme comprising education, resources and clinical support for intervention practices using proven behaviour change strategies
3. gather outcomes and costs
4. build research capacity within an ELENoR Primary Care Research Team and across a Primary Care Trust.

The primary outcome is the proportion of TB cases identified in primary care. The study is powered to detect a 20% increase (from 55% to 75%) in the detection of new cases of TB in primary care with 80% power at the 5% significance level. Secondary outcomes are rates of prophylaxis for latent TB infection (LTBI), BCG immunisation, smear negative (early) TB and costs. Analyses will be by intention to treat.


Options:
A: Intervention Type: PROCEDURE; Name: Quality Initiative in Rectal Cancer (QIRC) strategy; Assigned to Arm(s): N/A
B: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Other: Educational intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Educational intervention
C: Intervention Type: PROCEDURE; Name: Screening for Tuberculosis; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Opinion Leaders, Academic Detailing, Reminders, and Feedback; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind Trial of Methylene Blue for Cognitive Dysfunction in Bipolar Disorder
Brief Summary: While many bipolar patients treated with mood stabilizing medications experience improvement in their symptoms, some continue to have ongoing difficulties with concentration and memory. The purpose of this study is to look at whether these symptoms can be improved by adding the compound methylene blue to the treatment plan of patients who are already taking lamotrigine.

Methylene blue is an available 'over the counter medication' in Canada. It has been studied in the long-term treatment of mood symptoms in bipolar disorder. Several clinical studies done in bipolar disorder report that methylene blue has had positive effects on both cognition and mood. It is important to do further research in this area as we know that, for patients who continue to have ongoing cognitive difficulties, there is no recognized standard of care for bipolar patients who experience these type of deficits.


Options:
A: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: N-acetyl-cysteine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: N-acetyl-cysteine (NAC) | Arm Label: Aspirin and NAC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Dietary Supplement: N-acetyl-cysteine (NAC) | Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sugar Pill | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin, Aspirin and NAC | Intervention Type: DIETARY_SUPPLEMENT; Name: N-acetyl-cysteine (NAC); Assigned to Arm(s): Aspirin and NAC, N-acetyl-cysteine | Intervention Type: DRUG; Name: Sugar Pill; Assigned to Arm(s): Sugar Pill
B: Intervention Type: DRUG; Name: Methylene Blue; Assigned to Arm(s): N/A
C: Arm Label: memantine; Type: EXPERIMENTAL; Interventions: Drug: memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RO4995819 15 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4995819 | Arm Label: RO4995819 30 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4995819 | Arm Label: RO4995819 5 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4995819 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RO4995819; Assigned to Arm(s): RO4995819 5 mg | Intervention Type: DRUG; Name: RO4995819; Assigned to Arm(s): RO4995819 15 mg | Intervention Type: DRUG; Name: RO4995819; Assigned to Arm(s): RO4995819 30 mg

Answer: B